Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has provided an announcement.
Lumos Diagnostics Holdings Ltd has issued 5,000,000 fully paid ordinary shares following the exercise of options by SBC Global Investment Funds. This issuance was conducted without investor disclosure under specific provisions of the Corporations Act. The company is preparing its annual report and planning a pediatric study for its FebriDx product, with ongoing discussions for potential non-dilutive funding.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics specializes in rapid, cost-effective, and comprehensive point-of-care diagnostic test technology, aiding healthcare professionals in accurately diagnosing and managing medical conditions. The company offers customized assay development, manufacturing services for POC tests, and proprietary digital reader platforms, focusing on infectious and inflammatory diseases.
Average Trading Volume: 6,088,971
Technical Sentiment Signal: Buy
Current Market Cap: A$71.86M
Find detailed analytics on LDX stock on TipRanks’ Stock Analysis page.